Keystone Symposia in Santa Fe

Integrated Pathways of Disease in NASH and NAFLD

Eldorado Hotel | Santa Fe, New Mexico, USA | January 20–24, 2019

Scientific Organizers:
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
Brent A. Tetri, Saint Louis University, USA
Mary E. Rinella, Northwestern University, USA
Christopher R. Shepard, Structured Bioequity (SBE), USA

The global prevalence of nonalcoholic fatty liver disease (NAFLD) has risen precipitously over the past two decades in parallel with the worldwide obesity epidemic; however, there are no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of liver cancer. Despite the growing number of systemic and liver-specific abnormalities identified in patients with NAFLD, a clear hierarchy of the relative importance of specific defects has not emerged. Furthermore, a clear understanding of which individuals are at greatest risk for progression to advanced liver disease and cancer remains elusive. Thus, the field lacks an integrated understanding of risk prediction, pathogenesis and validated biomarkers to predict or track disease progression without reliance on liver biopsies. Therefore, the goals of this conference are to: 1) Explore genetic and ethnic contributions to NAFLD development; 2) Clarify underlying pathogenic defects in NAFLD and NASH, focusing on the specific contributions of lipotoxicity, the microbiome, innate immune signaling and drivers of fibrosis; and 3) Highlight emerging prognostic and diagnostic biomarkers that are yielding new, more streamlined clinical trial designs to evaluate novel therapies. As a result of this conference, attendees should gain a more holistic understanding of the unmet needs and new paths to advancing our understanding of NAFLD pathogenesis, diagnosis and therapy. The multidisciplinary nature of the topics and speakers promises to generate novel insights that represent convergent expertise and opinion. In doing so, new paradigms are likely to emerge that greatly inform the expanding number of emerging diagnostic markers and therapeutic agents. The conference comes at a propitious time when there is already sufficient basic translational and clinical research to extract important new insights, focus on unmet needs and refine research strategies for the future.

Plenary Session Topics:
- Genetic / Ethnic Determinants and Natural History of NAFLD
- Workshop 1: Biomarkers
- Metabolic Drivers of Cell Stress and Injury
- Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
- Workshop 2: Therapeutics
- Innate Immune and Inflammatory Signaling
- Integrative and Systemic Biology of NAFLD
- Fibrosis and Cancer – Mechanisms and Markers
- Modalities of NAFLD Diagnosis and Prognosis Assessment
- Workshop 3: Animal Models
- Clinical Trial Design and Emerging Therapies

Scholarship/Discounted Abstract Deadline: Oct 2, 2018; Abstract Deadline: Oct 24, 2018; Discounted Registration Deadline: Nov 27, 2018

Visit **www.keystonesymposia.org/19A4** for more details.





KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery
a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

Integrated Pathways of Disease in NASH and NAFLD (A4)

January 20-24, 2019 • Eldorado Hotel & Spa • Santa Fe, New Mexico, USA

Scientific Organizers: Scott L. Friedman, Arun J. Sanyal, Brent A. Tetri, Mary E. Rinella and Christopher R. Shepard

Sponsored by Gilead Sciences, Inc.

Abstract & Scholarship Deadline: October 2, 2018 / Abstract Deadline: October 24, 2018 / Discounted Registration Deadline: November 27, 2018

SUNDAY, JANUARY 20

Arrival and Registration

MONDAY, JANUARY 21

Welcome and Keynote Address

Gökhan S. Hotamisligil, Harvard University, USA
Metainflammation and Fatty Liver Disease

Genetic / Ethnic Determinants and Natural History of NAFLD

Stefano Romeo, University of Gothenburg, Sweden
Genetic Drivers of NAFLD

Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
The Dynamic Nature of NAFLD: A Critical Analysis of Disease Progression and Regression

Vincent WS Wong, Chinese University of Hong Kong, Hong Kong
NAFLD across the World – Similarities and Differences

Short Talk(s) Chosen from Abstracts

Workshop 1: Biomarkers

Short Talks Chosen from Abstracts

Metabolic Drivers of Cell Stress and Injury

Harmeet Malhi, Mayo Clinic, USA
Lipotoxic Stress and the Pathogenesis of NASH

Michael Trauner, Medical University of Vienna, Austria
Bile Acid Regulation of Metabolism in the Development and Progression of NAFLD

Johan Auwerx, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland
Systems Biology

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, JANUARY 22

Drivers and Consequences of Hepatic Lipotoxicity in NAFLD

Brent A. Tetri, Saint Louis University, USA
Fatty Acid Dysregulation in NAFLD

Petra Hirsova, Mayo Clinic, USA
Death Receptor Signaling and Cell Injury NASH

Sheila Collins, Vanderbilt University Medical Center, USA
Thermogenesis and Energy Utilization

James P. Hardwick†, Northeast Ohio Medical University, USA
Cytochrome P450-mediated Lipotoxicity

Short Talk(s) Chosen from Abstracts

Workshop 2: Therapeutics

Short Talks Chosen from Abstracts

Innate Immune and Inflammatory Signaling

Gyongyi Szabo, University of Massachusetts Medical School, USA
Innate Immune Cell Activation in NASH: Mechanisms and Therapeutic Targets

Wajahat Z. Mehal, Yale University, USA
Innate Immune Signaling and NASH

Speaker to be Announced

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, JANUARY 23

Integrative and Systemic Biology of NAFLD

Thomas P. Burris, St. Louis University School of Medicine, USA
Targeting Orphan Nuclear Receptors for Treatment of NASH

Li Li, Icahn School of Medicine at Mount Sinai, USA
Therapeutic Stratification of Patients with NASH and NAFLD Based on Phenomic Profiles from Electronic Medical Data

Ira Tabas, Columbia University, USA
Adipocyte Biology

Ariel E. Feldstein, University of California, San Diego, USA
Extracellular Vesicles as Systemic Mediators of NASH

Short Talk(s) Chosen from Abstracts

Fibrosis and Cancer – Mechanisms and Markers

Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Stellate Cell Biology

Jelena Mann, Newcastle University, UK
Epigenetics of Fibrosis and Cancer in Liver Disease

Chinweike Ukomadu, Novartis Institutes for Biomedical Research, USA
Addressing New Molecular Targets for the Treatment of NASH

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, JANUARY 24

Modalities of NAFLD Diagnosis and Prognosis Assessment

Tina S. Nova, Molecular Stethoscope, USA
Biomarkers and NASH

Rohit Loomba, University of California, San Diego, USA
Serum and Imaging Biomarkers

Sangeeta N. Bhatia, Massachusetts Institute of Technology, USA
Assessing Matrix Turnover and Proteolysis

Yi Luo, Bristol-Myers Squibb, USA
Serum Protein Biomarkers of NASH

Short Talk(s) Chosen from Abstracts

Workshop 3: Animal Models

Short Talks Chosen from Abstracts

Clinical Trial Design and Emerging Therapies

Mary E. Rinella, Northwestern University, USA
Clinical Trial Design, Endpoints and Regulatory Science in NAFLD
Accelerating Patient Accrual and Shortening Trial Length

Christopher R. Shepard, Evo Bio
mRNA Therapeutics

Geoffrey von Maltzahn, Seres Therapeutics, USA
Microbiome Therapeutics

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, JANUARY 25

Departure